Lupin Limited is a transnational pharmaceutical company primarily engaged in the production, development, and marketing of generic and branded formulations, biotech products, and active pharmaceutical ingredients globally.

The company reported record-high revenues and EBITDA for Q2 FY26, showcasing substantial growth driven by new product launches and strong market performance across major regions like the U.S. and India.

Lupin is heavily investing in expanding its complex generics and biosimilars portfolio, expecting these high-value segments to significantly contribute to its future revenue streams, especially in regulated markets like the U.S.

Notably, Lupin is enhancing its specialty business through key acquisitions, such as the impending acquisition of VISUfarma, and strategic partnerships to strengthen its market position in high-growth therapeutic areas such as ophthalmology.

The company's commitment to operational excellence and compliance has resulted in impressive ESG achievements, including an S&P Global ESG score of 91/100, positioning it as a sustainability leader within the pharmaceutical industry.